Trial · NCT02922764
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT02922764, Phase 1, Completed, Inspirna, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer. Trials, record NCT02922764. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02922764
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
- NCT number
- NCT02922764
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 146 participants, actual
- Lead sponsor
- Inspirna, Inc.
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
- Interventions
- RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
- First posted
- 2016-10-04
- Last updated
- 2025-03-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum tolerated dose (MTD), or the maximum tested dose at which multiple DLTs are not observed, of RGX-104 as a single agent, and separately, in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed. | 6 months | |
| Primary | Overall response rate associated with RGX-104 treatment as a single agent, and separately, in combination with docetaxel or pembrolizumab plus carboplatin/pemetrexed. | 24 months | |
| Primary | Progression-free survival associated with RGX-104 treatment as a single agent, and separately, in combination with docetaxel or pembrolizumab plus carboplatin/pemetrexed. | 24 months | |
| Primary | Number of participants with treatment-emergent adverse events associated with RGX-104 treatment as a single agent, and separately, in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed. | 24 months | |
| Secondary | Pharmacokinetics: Maximum Plasma Concentration (Cmax) of RGX-104. | 24 months | |
| Secondary | Pharmacokinetics: Area Under the Curve (AUC) of RGX-104. | 24 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02922764
GET https://conductscience.org/api/trials/v1/NCT02922764/registered